Donghai Securities released a research report on April 23 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is in line with expectations, and overall cost control is good; 2) ensartinib is growing rapidly, and the volume of new drugs is expected to be marketed in 24 years; 3) the R&D pipeline continues to advance, and endogenous development and external cooperation go hand in hand. (Mainichi Keizai Shimbun)
东海证券4月23日发布研报称，给予贝达药业（300558.SZ）买入评级。评级理由主要包括：1）利润端符合预期，整体费用控制良好；2）恩沙替尼快速增长，期待上市新药24年放量；3）研发管线持续推进，内生发展与外部合作齐发力。（每日经济新闻）
Donghai Securities released a research report on April 23 stating that it gave Betta Pharmaceuticals (300558.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is in line with expectations, and overall cost control is good;
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.